Skip to main content

IQVIA Holdings Value Stock - Dividend - Research Selection

Iqvia s

ISIN: US46266C1053 , WKN: A2JSPM

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Peering Into IQVIA Hldgs's Recent Short Interest

2024-03-29
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), United Therapeutics (UTHR) and Immunome (IMNM)

2024-03-29
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

IQVIA Holdings Inc. stock underperforms Tuesday when compared to competitors

2024-03-26
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Insiders At IQVIA Holdings Sold US$10m In Stock, Alluding To Potential Weakness

2024-03-25
The fact that multiple IQVIA Holdings Inc. ( NYSE:IQV ) insiders offloaded a considerable amount of shares over the...

Tracking William Nygren's Harris Associates Portfolio - Q4 2023 Update

2024-03-24
Harris Associates' 13F portfolio value increased from $51.39B to $58.34B in Q4 2023. Read more about William Nygren's holdings and trades.

Why Is Tandem Diabetes Care (TNDM) Up 27.4% Since Last Earnings Report?

2024-03-22
Tandem Diabetes Care (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IQVIA Holdings Inc. stock underperforms Friday when compared to competitors

2024-03-22
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

25 Countries With Limited Access To Healthcare

2024-03-20
In this article, we will be taking a look at the 25 countries with limited access to health care. If you do not want to learn about the global healthcare market, head straight to the 5 Countries With Limited Access To Healthcare. Access to healthcare is a fundamental human right, yet many countries around the […]

Here's Why We Think IQVIA Holdings (NYSE:IQV) Might Deserve Your Attention Today

2024-03-20
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

NASH drug market expected to surpass $48B by 2035

2024-03-16
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.